abstract |
including, but not limited to, multiple myeloma, acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), or blastic plasmacytoid dendritic cell neoplasm (BPDCN); Disclosed are genetically modified NK cells comprising a knockout of the surface antigen class 38 (CD38) gene and methods of using the same for treating cancer. [Selection drawing] Fig. 12-3 |